Brief: Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
15/12/2025 12:10
Dec 15 (Reuters) - ABPRO Holdings Inc ABP.O: ABPRO HOLDINGS ANNOUNCES SUBMISSION OF AN IND APPLICATION TO INITIATE A PHASE 1 CLINICAL TRIAL OF T CELL ENGAGER ABP-102/CT-P72 FOR HER2-POSITIVE CANCERS ABPRO HOLDINGS INC - PHASE 1 TRIAL FOR HER2-POSITIVE CANCERS EXPECTED IN 1H 2026 Source text: ID:nGNX8mCv3l Further company coverage: ABP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABPRO Holdings
See all newsBrief: Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
Brief: Abpro Holdings Files Prospectus Related To The Offer And Resale Of Up To 9.78 Million Shares Of Common Stock - SEC Filing
Brief: Abpro Holdings Inc - To Effect One-For-Thirty Reverse Stock Split - SEC Filing
Brief: ABPRO Announces Oral Presentation Of First Preclinical Data For ABP-102/CT-P72, A Tetravalent Bispecific HER2 X CD3 T-Cell Engager, At AACR Annual Meeting 2025
Brief: Abpro Holdings Inc Terminates Ian Chan As CEO Effective March 3, 2025